Theravance Biopharma reports positive data from trials conducted on VIBATIV

2nd November 2016 (Last Updated November 2nd, 2016 18:30)

US-based biopharmaceutical company Theravance has reported positive results from trials of VIBATIV (telavancin) in treating osteomyelitis and combat methicillin-resistant staphylococcus aureus (MRSA) pathogens.

US-based biopharmaceutical company Theravance has reported positive results from trials of VIBATIV (telavancin) in treating osteomyelitis and combat methicillin-resistant staphylococcus aureus (MRSA) pathogens.

Analysis of a retrospective trial examining 32 osteomyelitis patients suggested that administration of VIBATIV cured or improved 87.5% patients, which rose to 91.3% after three months of the end of the treatment.

The study recorded staphylococcus aureus as the most common pathogen, infecting 18 patients.

Theravance clinical development and medical affairs vice-president Jon Bruss said: "Although osteomyelitis is not currently an approved indication for VIBATIV, these encouraging study results merit further investigation and may suggest that osteomyelitis, particularly when caused by MRSA, is another serious infection type, against which VIBATIV appears to have had positive clinical outcomes.”

"The study recorded staphylococcus aureus as the most common pathogen, infecting 18 patients."

Another study demonstrated the in-vitro activity of VIBATIV while assessing difficult-to-treat MRSA pathogens collected from a community hospital in the mid-Michigan area.

VIBATIV was observed as bactericidal and resulted in a rapid and prolonged decrease in pathogen levels.

Analysis of a previously completed Phase III Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia (ATTAIN) study comparing VIBATIV to vancomycin suggested similar overall healthcare costs incurred by both VIBATIV and vancomycin.

During the ATTAIN studies, renal shift tables were created by grouping patients based on creatinine clearance levels.

Researchers observed that 67% of VIBATIV-treated patients and 63% of vancomycin-treated patients experienced no categorical shifts in creatinine clearance, suggesting minimal effect of the treatment on the patient’s renal function.

Bruss added: "Interestingly, our retrospective analytical modelling of data from the ATTAIN studies highlights a specific patient population that not only achieved better clinical outcomes with VIBATIV but also incurred lower overall healthcare costs as compared to vancomycin.”

VIBATIV has been developed as a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with in-vitro potency and a dual mechanism of action inhibiting both bacterial cell wall synthesis and disrupting bacterial cell membrane function.